Hepatitis Forums
Fatty Liver Disease Main Forums => Nonalcoholic Steatohepatitis (NASH) => Topic started by: Hep Editors on January 21, 2020, 11:45:26 am
-
Tropifexor, a highly potent FXR agonist, led to a significant decline in weight and liver enzyme levels 12 weeks into a 48-week study among people with non-alcoholic steatohepatitis (NASH).
Arun Sanyal, MD, of Virginia Commonwealth University School of Medicine in Richmond, presented interim findings from the ongoing, randomized, double-blind, placebo-controlled Phase II FLIGHT-FXR study of tropifexor at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Diseases, this month in Boston.
The previously reported interim results from parts A and B of the study, in which participants received between 10 and 90 micrograms of tropifexor daily, showed evidence that the drug affected the intended targets and reduced both inflammation and the level of fat in the liver without causing major changes in blood lipids.
Read more...
https://www.hepmag.com/article/tropifexor-shows-promise-treatment-nash